Correlation between macular structure and function in patients with age-related macular degeneration treated with intravitreal ranibizumab: 12-month-results
- 59 Downloads
To determine the significance of the correlation between optical coherence tomographic (OCT) findings and focal macular electroretinograms (fmERG) at 12 months after beginning intravitreal injections of ranibizumab (IVR) in eyes with age-related macular degeneration (AMD).
Prospective, clinical study.
We studied 28 eyes of 28 patients with AMD treated with IVR at monthly intervals for the initial three months. Additional IVR was given according to a pro re nata (PRN) regimen. OCT and fmERGs were performed preoperatively and at 3 and 12 months postoperatively. The fmERGs were elicited by a 15° white stimulus spot centered on the fovea. The thickness of the inner, middle, and outer layers of the retina and also of the serous retinal detachment (SRD) and pigment epithelial detachment (PED) in the horizontal and vertical meridians at 1.2 mm from the fovea (parafoveal) were measured in the OCT images.
The b-wave amplitude at 12 months was significantly correlated with the thicknesses of the outer retinal layer, SRD, and PED (P=0.001–0.02). Multiple regression analyses showed that the outer retinal layer thickness was an independent determinant (P= 0.0001). The changes in the b-wave amplitude between the baseline and 12 months were significantly correlated with the changes in the SRD thickness (P=0.006). The changes in the b-wave amplitude during the PRN period were significantly correlated with the changes in the PED thickness (P=0.02).
At 12 months after beginning treatment, the reduction in the SRD thickness affects macular function recovery. As recurrences of the PED can occur during the PRN period, control of the PED is necessary to obtain good macular function for the long term.
KeywordsAge-related macular degeneration Intravitreal ranibizumab Focal macular electroretinogram Serous retinal detachment Pigment epithelial detachment
Conflicts of interest
T. Nishimura, None; S. Machida, None.
- 6.Johnston RL, Lee AY, Buckle M, Antcliff R, Bailey C, McKibbin M, UK AMD EMR Users Group, et al. UK age-related macular degeneration electronic medical record system (AMD EMR) users group report IV: incidence of blindness and sight impairment in ranibizumab-treated patients. Ophthalmology. 2016;123:2386–92.CrossRefGoogle Scholar
- 9.Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119:1388–98.CrossRefGoogle Scholar
- 14.Nishimura T, Machida S, Harada T, Kurosaka D. Retinal ganglion cell function after repeated intravitreal injections of ranibizumab in patients with age-related macular degeneration. Clin Ophthalmol. 2012;6:1073–82.Google Scholar
- 17.Miyake Y, Yanagida K, Kondo K, Ota I. Subjective scotometry and recording of local electroretinogram and visual evoked response. System with television monitor of the fundus. Jpn J Ophthalmol. 1981;25:439–48.Google Scholar
- 18.Miyake Y. Studies of local macular ERG. Acta Soc Ophthalmol Jpn. 1988;92:1419–49.Google Scholar
- 25.Sharma S, Toth CA, Daniel E, Grunwald JE, Maguire MG, Ying GS, Comparison of Age-related Macular Degeneration Treatments Trials Research Group, et al. Macular morphology and visual acuity in the second year of the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2016;123:865–75.CrossRefGoogle Scholar
- 32.Essex RW, Nguyen V, Walton R, Arnold JJ, McAllister IL, Guymer RH, Fight Retinal Blindness Study Group, et al. Treatment patterns and visual outcomes during the maintenance phase of treat-and-extend therapy for age-related macular degeneration. Ophthalmology. 2016;123:2393–400.CrossRefGoogle Scholar
- 35.Yun C, Oh J, Ahn J, Hwang SY, Lee B, Kim SW, et al. Comparison of intravitreal aflibercept and ranibizumab injections on subfoveal and peripapillary choroidal thickness in eyes with neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2016;254:1693–702.CrossRefGoogle Scholar